Bevacuzimab ELISA Assay Kit

Bevacuzimab ELISA Assay Kit

$1,080.00

The Bevacuzimab ELISA Assay Kit is used as an analytical tool for quantitative determination of Bevacizumab in serum, plasma and cell culture supernatant.

SKU: KBI1016 Categories: , ,

Bevacuzimab ELISA Assay Kit

The Bevacuzimab ELISA Assay Kit is For Research Use Only

Size: 12×8 wells
Sensitivity: <1.56 ng/mL
Standard Range: 1.56-100 ng/ml
Incubation Time: 2.5 hours
Sample Type: Serum, Plasma, Cell Culture Supernatants
Sample Size: 100 µL
Alternative Name: Avastin

Assay Principle

The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Bevacizumab are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Bevacizumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti-Bevacizumab antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Bevacizumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.

Sample Preparation and Storage:
Blood is taken by venipuncture. Serum is separated after clotting by centrifugation. Plasma can be used, too. Lipaemic, hemolytic or contaminated samples should not be run. Repeated freezing and thawing should be avoided. If samples are to be used for several assays, initially aliquot samples and keep at – 20°C. For Cell Culture Supernatant – If necessary, centrifuge to remove debris prior to analysis. Samples can be stored at -20°C or -80⁰C. Avoid repeated freeze-thaw cycles.

Related Products to Bevaxuzimab ELISA

Anti-Bevacuzimab (Avastin) ELISA Kit
Bevacizumab mAb-based ELISA Assay
Trastuzumab (Herceptin) ELISA

Additional Information

Assay Background

Bevacizumab is a recombinant Human IgG;κ monoclonal antibody specific for all human vascular endothelial growth factor A (VEGF-A) isoforms. Additionally, Bevacizumab binds to and neutralizes all human VEGF-A isoforms in bioactive proteolytic fragments, but not mouse or rat VEGF.

Assay Procedure

1. It is strongly recommended that all Controls and Samples be run in duplicates or triplicates. A standard curve is required for each assay. All steps must be performed at 37°C
2. Pipette out 25 μl of Assay Diluent in each well.
3. Pipette out 25 μl of Anti-Bevacizumab: HRP Conjugate in each well.
4. Pipette 100 μl of Standards or Samples into the respective wells.
5. Cover the plate and incubate for 120 minutes at 37°C
6. Aspirate and wash plate 4 times with Wash Buffer (1X) and blot residual buffer by firmly tapping plate upside down on absorbent paper. Wipe off any liquid from the bottom outside of the microtiter wells as any residue can interfere in the reading step.
7. Add 100 μl of TMB Substrate in each well.
8. Incubate the plate at 37°C for 30 minutes in dark. DO NOT SHAKE or else it may result in higher backgrounds and worse precision. Positive wells should turn bluish in color.
9. Pipette out 100 μl of Stop Solution. Wells should turn from blue to yellow in color.
10. Read the absorbance at 450 nm with a microplate reader.

Package Inserts

Please note: All documents above are for reference use only and should not be used in place of the documents included with this physical product. If digital copies are needed, please contact us.

Product Citations